SGLT-2 inhibitors: a step forward in the treatment of heart failure with reduced ejection fraction

Detalhes bibliográficos
Autor(a) principal: Silva-Cardoso, José
Data de Publicação: 2021
Outros Autores: Andrade, Aurora, Brito, Dulce, Ferreira, Jorge, Fonseca, Cândida, Peres, Marisa, Franco, Fátima, Moura, Brenda
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10451/49549
Resumo: © Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
id RCAP_5e2085428bf79e73a07eeceeb8cc33ad
oai_identifier_str oai:repositorio.ul.pt:10451/49549
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling SGLT-2 inhibitors: a step forward in the treatment of heart failure with reduced ejection fractionInibidores do SGLT-2: um passo em frente no tratamento da ICFErCanagliflozinCardiovascular mortalityDapagliflozinEmpagliflozinErtugliflozinHeart failureHeart failure hospitalizationSGLT-2 inhibitorsSotagliflozinType-2 diabetes mellitus© Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)Heart failure (HF) is a major health problem with a significant impact on morbidity, mortality, quality of life and healthcare costs. Despite the positive impact of disease-modifying therapies developed over the last four decades, HF mortality and hospitalization remain high. We aim at reviewing the evidence supporting the use of sodium-glucose co-transporter-2 (SGLT-2) inhibitors, as a novel strategy for HF with reduced ejection fraction (HFrEF) treatment. The consistent observation of a reduction in HF hospitalizations in type-2 diabetes cardiovascular safety trials EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58 and VERTIS raised the hypothesis that SGLT-2 inhibitors could have an impact in HF treatment. This hypothesis was first confirmed in 2019 with the DAPA-HF publication showing that dapagliflozin on top of optimized HFrEF therapy, reduced HF-hospitalizations and cardiovascular mortality. This was reinforced by the EMPEROR-Reduced publication in 2020 showing that empagliflozin on top of optimized HFrEF therapy, reduced HF-hospitalizations. Both studies established SGLT-2 inhibitors as a fourth pillar of HFrEF prognosis-modifying therapy, in addition to the gold standard triple neurohormonal modulation/blockade.ElsevierRepositório da Universidade de LisboaSilva-Cardoso, JoséAndrade, AuroraBrito, DulceFerreira, JorgeFonseca, CândidaPeres, MarisaFranco, FátimaMoura, Brenda2021-09-20T14:58:52Z20212021-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/49549engRev Port Cardiol (Engl Ed). 2021 Sep;40(9):687-69310.1016/j.repce.2021.02.0062174-2049info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T16:53:25Zoai:repositorio.ul.pt:10451/49549Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T22:01:10.678764Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv SGLT-2 inhibitors: a step forward in the treatment of heart failure with reduced ejection fraction
Inibidores do SGLT-2: um passo em frente no tratamento da ICFEr
title SGLT-2 inhibitors: a step forward in the treatment of heart failure with reduced ejection fraction
spellingShingle SGLT-2 inhibitors: a step forward in the treatment of heart failure with reduced ejection fraction
Silva-Cardoso, José
Canagliflozin
Cardiovascular mortality
Dapagliflozin
Empagliflozin
Ertugliflozin
Heart failure
Heart failure hospitalization
SGLT-2 inhibitors
Sotagliflozin
Type-2 diabetes mellitus
title_short SGLT-2 inhibitors: a step forward in the treatment of heart failure with reduced ejection fraction
title_full SGLT-2 inhibitors: a step forward in the treatment of heart failure with reduced ejection fraction
title_fullStr SGLT-2 inhibitors: a step forward in the treatment of heart failure with reduced ejection fraction
title_full_unstemmed SGLT-2 inhibitors: a step forward in the treatment of heart failure with reduced ejection fraction
title_sort SGLT-2 inhibitors: a step forward in the treatment of heart failure with reduced ejection fraction
author Silva-Cardoso, José
author_facet Silva-Cardoso, José
Andrade, Aurora
Brito, Dulce
Ferreira, Jorge
Fonseca, Cândida
Peres, Marisa
Franco, Fátima
Moura, Brenda
author_role author
author2 Andrade, Aurora
Brito, Dulce
Ferreira, Jorge
Fonseca, Cândida
Peres, Marisa
Franco, Fátima
Moura, Brenda
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Silva-Cardoso, José
Andrade, Aurora
Brito, Dulce
Ferreira, Jorge
Fonseca, Cândida
Peres, Marisa
Franco, Fátima
Moura, Brenda
dc.subject.por.fl_str_mv Canagliflozin
Cardiovascular mortality
Dapagliflozin
Empagliflozin
Ertugliflozin
Heart failure
Heart failure hospitalization
SGLT-2 inhibitors
Sotagliflozin
Type-2 diabetes mellitus
topic Canagliflozin
Cardiovascular mortality
Dapagliflozin
Empagliflozin
Ertugliflozin
Heart failure
Heart failure hospitalization
SGLT-2 inhibitors
Sotagliflozin
Type-2 diabetes mellitus
description © Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
publishDate 2021
dc.date.none.fl_str_mv 2021-09-20T14:58:52Z
2021
2021-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10451/49549
url http://hdl.handle.net/10451/49549
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Rev Port Cardiol (Engl Ed). 2021 Sep;40(9):687-693
10.1016/j.repce.2021.02.006
2174-2049
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134559937232896

Registros relacionados